Main D M, Main E K, Strong S E, Gabbe S G
Am J Obstet Gynecol. 1985 Aug 15;152(8):1031-3. doi: 10.1016/0002-9378(85)90553-8.
Intravenous ritodrine therapy can cause significant deterioration of maternal glucose homeostasis. We investigated the effect of full maintenance oral ritodrine therapy (120 mg/day) on glucose tolerance in the early third trimester with the use of 50 gm 1-hour screens followed by 100 gm 3-hour oral glucose tolerance tests if the screen level was greater than or equal to 140 mg/dl. Four hundred ninety-one patients were studied, 42 of whom were receiving oral ritodrine therapy. Twenty-one percent of the ritodrine-treated women had an abnormal 1-hour screen, which was not different from the 20% observed in women not receiving therapy. None of the treated group and 13% of the untreated group who had abnormal screens had abnormal oral glucose tolerance tests. The probability of an abnormal test after an abnormal 1-hour screen was also determined.
静脉注射利托君治疗可导致母体葡萄糖稳态显著恶化。我们采用50克1小时筛查,若筛查水平大于或等于140毫克/分升,则接着进行100克3小时口服葡萄糖耐量试验,研究了孕晚期早期全程维持口服利托君治疗(120毫克/天)对葡萄糖耐量的影响。共研究了491例患者,其中42例接受口服利托君治疗。接受利托君治疗的女性中有21%的人1小时筛查异常,这与未接受治疗的女性中观察到的20%并无差异。筛查异常的治疗组中无一例口服葡萄糖耐量试验异常,未治疗组中有13%筛查异常者口服葡萄糖耐量试验异常。还确定了1小时筛查异常后试验异常的概率。